S&P 500   3,326.36 (+0.60%)
DOW   27,135.98 (+1.15%)
QQQ   271.22 (+0.31%)
AAPL   437.25 (-0.32%)
MSFT   213.09 (-0.09%)
FB   250.23 (+0.16%)
GOOGL   1,479.58 (+0.43%)
AMZN   3,206.78 (+2.16%)
NVDA   452.69 (+0.80%)
CGC   19.07 (-1.29%)
BABA   265.11 (+1.11%)
TSLA   1,492.02 (+0.34%)
MU   50.95 (-0.68%)
GE   6.24 (+1.63%)
AMD   84.86 (-0.21%)
T   29.82 (-0.63%)
F   7.01 (+2.04%)
ACB   10.63 (-0.93%)
GILD   69.31 (-2.22%)
NFLX   505.62 (-0.79%)
DIS   128.21 (+9.31%)
BAC   25.41 (+1.60%)
BA   172.22 (+4.33%)
S&P 500   3,326.36 (+0.60%)
DOW   27,135.98 (+1.15%)
QQQ   271.22 (+0.31%)
AAPL   437.25 (-0.32%)
MSFT   213.09 (-0.09%)
FB   250.23 (+0.16%)
GOOGL   1,479.58 (+0.43%)
AMZN   3,206.78 (+2.16%)
NVDA   452.69 (+0.80%)
CGC   19.07 (-1.29%)
BABA   265.11 (+1.11%)
TSLA   1,492.02 (+0.34%)
MU   50.95 (-0.68%)
GE   6.24 (+1.63%)
AMD   84.86 (-0.21%)
T   29.82 (-0.63%)
F   7.01 (+2.04%)
ACB   10.63 (-0.93%)
GILD   69.31 (-2.22%)
NFLX   505.62 (-0.79%)
DIS   128.21 (+9.31%)
BAC   25.41 (+1.60%)
BA   172.22 (+4.33%)
S&P 500   3,326.36 (+0.60%)
DOW   27,135.98 (+1.15%)
QQQ   271.22 (+0.31%)
AAPL   437.25 (-0.32%)
MSFT   213.09 (-0.09%)
FB   250.23 (+0.16%)
GOOGL   1,479.58 (+0.43%)
AMZN   3,206.78 (+2.16%)
NVDA   452.69 (+0.80%)
CGC   19.07 (-1.29%)
BABA   265.11 (+1.11%)
TSLA   1,492.02 (+0.34%)
MU   50.95 (-0.68%)
GE   6.24 (+1.63%)
AMD   84.86 (-0.21%)
T   29.82 (-0.63%)
F   7.01 (+2.04%)
ACB   10.63 (-0.93%)
GILD   69.31 (-2.22%)
NFLX   505.62 (-0.79%)
DIS   128.21 (+9.31%)
BAC   25.41 (+1.60%)
BA   172.22 (+4.33%)
S&P 500   3,326.36 (+0.60%)
DOW   27,135.98 (+1.15%)
QQQ   271.22 (+0.31%)
AAPL   437.25 (-0.32%)
MSFT   213.09 (-0.09%)
FB   250.23 (+0.16%)
GOOGL   1,479.58 (+0.43%)
AMZN   3,206.78 (+2.16%)
NVDA   452.69 (+0.80%)
CGC   19.07 (-1.29%)
BABA   265.11 (+1.11%)
TSLA   1,492.02 (+0.34%)
MU   50.95 (-0.68%)
GE   6.24 (+1.63%)
AMD   84.86 (-0.21%)
T   29.82 (-0.63%)
F   7.01 (+2.04%)
ACB   10.63 (-0.93%)
GILD   69.31 (-2.22%)
NFLX   505.62 (-0.79%)
DIS   128.21 (+9.31%)
BAC   25.41 (+1.60%)
BA   172.22 (+4.33%)
Log in

NASDAQ:SRRASierra Oncology Stock Price, Forecast & News

$11.74
-0.31 (-2.57 %)
(As of 08/5/2020 02:50 PM ET)
Add
Compare
Today's Range
$11.66
Now: $11.74
$12.01
50-Day Range
$10.90
MA: $12.68
$15.30
52-Week Range
$8.55
Now: $11.74
$22.00
Volume1,121 shs
Average Volume33,739 shs
Market Capitalization$122.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. The company is also advancing SRA737, which is being investigated in two Phase 1/2 clinical trials primarily focused on patients with ovarian cancer; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More
Sierra Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRRA
Previous SymbolNASDAQ:DNAI
CUSIPN/A
Phone604-558-6536

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$8.93 per share

Profitability

Net Income$-88,280,000.00

Miscellaneous

Employees79
Market Cap$122.10 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable
$11.74
-0.31 (-2.57 %)
(As of 08/5/2020 02:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

How has Sierra Oncology's stock been impacted by COVID-19 (Coronavirus)?

Sierra Oncology's stock was trading at $11.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SRRA shares have increased by 1.2% and is now trading at $11.74.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Sierra Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sierra Oncology
.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Sierra Oncology
.

How were Sierra Oncology's earnings last quarter?

Sierra Oncology Inc (NASDAQ:SRRA) issued its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($2.74) by $1.43.
View Sierra Oncology's earnings history
.

What price target have analysts set for SRRA?

2 equities research analysts have issued 12-month target prices for Sierra Oncology's stock. Their forecasts range from $20.00 to $48.00. On average, they anticipate Sierra Oncology's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 189.6% from the stock's current price.
View analysts' price targets for Sierra Oncology
.

Has Sierra Oncology been receiving favorable news coverage?

Headlines about SRRA stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sierra Oncology earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days.
View the latest news about Sierra Oncology
.

Are investors shorting Sierra Oncology?

Sierra Oncology saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 4,700 shares, a drop of 65.2% from the June 30th total of 13,500 shares. Based on an average trading volume of 27,800 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company's shares are sold short.
View Sierra Oncology's Current Options Chain
.

Who are some of Sierra Oncology's key competitors?

What other stocks do shareholders of Sierra Oncology own?

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the following people:
  • Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)
  • Dr. Barbara Klencke, Chief Devel. Officer (Age 62)
  • Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)
  • Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)
  • Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50)

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include Signaturefd LLC (0.05%). Company insiders that own Sierra Oncology stock include Andrew R Allen and Barbara Klencke.
View institutional ownership trends for Sierra Oncology
.

Which major investors are buying Sierra Oncology stock?

SRRA stock was purchased by a variety of institutional investors in the last quarter, including Signaturefd LLC. Company insiders that have bought Sierra Oncology stock in the last two years include Andrew R Allen, and Barbara Klencke.
View insider buying and selling activity for Sierra Oncology
.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $11.74.

How big of a company is Sierra Oncology?

Sierra Oncology has a market capitalization of $122.10 million. The biotechnology company earns $-88,280,000.00 in net income (profit) each year or ($19.52) on an earnings per share basis. Sierra Oncology employs 79 workers across the globe.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is www.sierraoncology.com.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150 - 885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.